GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye, New Study Finds
A new study presented at the American Academy of Ophthalmology suggests that patients taking GLP-1 weight-loss drugs may experience faster vision loss in their second eye if they have already suffered a stroke of the optic nerve. Researchers observed a higher frequency of rapid, sequential NAION events among users of these medications.
Why it matters
This finding highlights a potential significant side effect of popular weight-loss drugs, necessitating further clinical investigation into ocular health risks.
Newswise — For patients who lose vision in one eye to a sudden stroke of the optic nerve, there is a lingering fear that the other eye will eventually follow. A new study suggests that for people taking GLP-1 drugs, the popular class of medications used for diabetes and weight loss, that second blow may come sooner.
The research presented at the 130th annual meeting of the American Academy of Ophthalmology , found that among patients who developed the condition in both eyes, GLP-1 users were substantially more likely to have the second eye affected within six months of the first.
The condition, non-arteritic anterior ischemic optic neuropathy or NAION, happens when the optic nerve does not get enough blood flow, causing sudden, painless loss of vision in one eye. It typically strikes one eye. But it can affect the fellow eye.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in